Delcath Systems (DCTH) vs MiMedx Group (MDXG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Delcath Systems (DCTH) has outperformed MiMedx Group (MDXG) over the past year, gaining 35.5% versus a loss of 34.9%. Over five years, DCTH leads with a +59.8% price change compared with -31.7% for MDXG. MiMedx Group is the larger company by market cap ($681.5 million vs $533.0 million), about 1.3 times the size.
On valuation, MiMedx Group trades at a lower forward P/E (23.4x vs 341.3x for Delcath Systems).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DCTH | MDXG |
|---|---|---|
| Share price | $15.36 | $4.67 |
| Market cap | $532.97M | $681.51M |
| 1-day change | +2.13% | +1.08% |
| YTD return | +48.91% | -31.76% |
| 1-year return | +35.50% | -34.93% |
| 5-year return | +59.83% | -31.66% |
| P/E ratio (TTM) | — | 116.75 |
| Forward P/E | 341.33 | 23.35 |
| EPS (TTM) | $0.01 | $0.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.42 | $7.97 |
| 52-week low | $8.12 | $3.03 |
| Distance from 52-week high | -11.83% | -41.41% |
| Analyst consensus | none | none |
| Avg. price target upside | +56.25% | +58.46% |
| Average volume | 479.73K | 1.23M |
| Shares outstanding | 34.70M | 145.93M |
| Employees | 156 | 808 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DCTH has outperformed MDXG by 70.4 percentage points over the past year.
About Delcath Systems
DCTH stock →Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Health Care · Medical/Dental Instruments · 156 employees
About MiMedx Group
MDXG stock →MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare.
Health Care · Medical/Dental Instruments · 808 employees
DCTH vs MDXG FAQ
Which is bigger, Delcath Systems or MiMedx Group?
MiMedx Group (MDXG) is larger, with a market capitalization of $681.51M compared with $532.97M for Delcath Systems (DCTH).
Which stock has performed better over the past year, DCTH or MDXG?
DCTH returned +35.50% over the past 12 months, compared with -34.93% for MDXG (price return, excluding dividends). Past performance does not predict future results.
Are Delcath Systems and MiMedx Group in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.